Thetis Pharmaceuticals Presents Preclinical and Clinical Data at AACR Conference in Chicago
Preclinical Data Demonstrate TP-317 Acting Through BLT1Activates Innate Immune Cells to
Prime T-Cells, A Prerequisite for Anti-Tumor Immunity
Phase 1a Clinical Results Demonstrate a Favorable Safety Profile and
BLT1 Target Engagement In Healthy Volunteers
ESSEX, Conn.--—April 25, 2025—Thetis Pharmaceuticals LLC (“Thetis”), a clinical-stage company developing TP-317, a first-in-class, small molecule drug candidate targeting the BLT1 receptor to treat solid cancers today presentations at the 2025 AACR Annual Conference in Chicago, April 25 to May 1, 2025.
“The preclinical data support TP-317’s unique potential as an oral, first-in-class therapy that promotes antigen processing and presentation by innate immune cells to prime T-cells, a prerequisite for the efficacy of immune checkpoint inhibitors,” said Gary Mathias, CEO of Thetis Pharmaceuticals. “Our clinical data confirm safety, predictable pharmacokinetics, and BLT1 engagement in humans, and support dose selection for upcoming clinical trials.”
The presentations include:
S. Huang, et al. Resolvin E1 (RvE1) Enhances Immune Checkpoint Inhibitor Therapy by Stimulating Tumor Antigen-Presentation (see link)
J. Steinberg, Resolvin E1 (RvE1) in Solid Tumor Cancer: Towards Clinical Translation of a Novel Oral Agonist: Targeting the LTB4-BT1 Pathway to Enhance Immune Checkpoint Inhibitor (ICI) Therapy (see link)
About Thetis Pharmaceuticals
Thetis is a clinical-stage pharmaceutical company focused on developing innovative treatments for inflammatory bowel disease and solid cancers. Its lead candidate, TP-317, is a first-in-class oral RvE1 drug candidate that targets the LTB4-BLT1 pathway to mobilize the body’s natural ability to resolve disease and restore immune homeostasis. For more information, please visit www.thetispharma.com and follow us on LinkedIn.
Contact
Tracy Lessor
SVP, Communications
Thetis Pharma
617-519-9827
tracy@tlowcommunications.com